LOGIN  |  REGISTER
C4 Therapeutics
Assertio

Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024

October 31, 2024 | Last Trade: US$2.21 0.11 5.24

AUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a conference call on Thursday, November 7th at 8:30 a.m. Eastern Time.

Event details:
  
Date:Thursday, November 7th
Time:8:30 a.m. Eastern Time
Audio Webcast:https://www.CassavaSciences.com/company-presentations
Or
Audio Webcast:https://edge.media-server.com/mmc/p/tzb9j3sy

A replay of the audio webcast will also be available on the “Company Presentations” page of the Cassava Sciences website for 90 days following the webcast.

About Cassava Sciences, Inc.

Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease.

Simufilam is Cassava Sciences’ small molecule oral drug candidate currently in Phase 3 clinical trials for the treatment of Alzheimer's disease. Simufilam targets a specific site on filamin A, a scaffolding protein that is critical to certain receptor interactions in the brain. Cassava Sciences believes that simufilam interrupts amyloid-β42 binding to receptors in the brain and may affect the Alzheimer's disease process. Cassava Sciences owns exclusive, worldwide rights to its investigational product candidates and related technologies, without royalty obligations to any third party.

For more information, please visit: https://www.CassavaSciences.com

For More Information Contact:

Investors
Sandya van der Weid
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media
Sitrick And Company
This email address is being protected from spambots. You need JavaScript enabled to view it.

Company
Eric Schoen, Chief Financial Officer
(512) 501-2450
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page